Supplementary information 2
References of Tables 2, 3
1.
Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE, Boitnott J.
Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod
Pathol 2002;15:826-830.
2.
Guan J, Chen XP, Zhu H, Luo SF, Cao B, Ding L. Involvement of
extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in
multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol
2004;10:3522-3527.
3.
Zhu XD, Li CL, Lang ZW, Gao GF, Tien P. Significant correlation between
expression level of HSP gp96 and progression of hepatitis B virus induced diseases.
World J Gastroenterol 2004;10:1141-1145.
4.
Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Nagano H, Dono K,
Umeshita K, et al. Elevated expression of valosin-containing protein (p97) in
hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J
Clin Oncol 2003;21:447-452.
5.
Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, et al.
Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94)
in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J
Gastroenterol 2005;11:2072-2079.
6.
Suto K, Kajihara-Kano H, Yokoyama Y, Hayakari M, Kimura J, Kumano T,
Takahata T, et al. Decreased expression of the peroxisomal bifunctional enzyme and
carbonyl reductase in human hepatocellular carcinomas. J Cancer Res Clin Oncol
1999;125:83-88.
7.
Takezaki E, Murakami S, Nishibayashi H, Kagawa K, Ohmori H. [A clinical
study of complements as a marker of a hepatocellular carcinoma]. Gan No Rinsho
1990;36:2119-2122.
8.
Heinrich PC, Morris HP, Weber G. Behavior of transaldolase (EC 2.2.1.2) and
transketolase (EC 2.2.1.1) Activities in normal, neoplastic, differentiating, and
regenerating liver. Cancer Res 1976;36:3189-3197.
9.
Iguchi K, Murakami S, Matsumoto A, Shimizu A, Sakuragawa N.
Abnormally high level of antithrombin in a case with hepatocellular carcinoma.
Thromb Res 1996;84:137-141.
10.
Yoon GS, Lee H, Jung Y, Yu E, Moon HB, Song K, Lee I. Nuclear matrix of
calreticulin in hepatocellular carcinoma. Cancer Res 2000;60:1117-1120.
11.
Narasaka T, Moriya T, Endoh M, Suzuki T, Shizawa S, Mizokami Y,
Matsuoka
T,
et
al.
17Beta-hydroxysteroid
dehydrogenase
type
2
and
dehydroepiandrosterone sulfotransferase in the human liver. Endocr J 2000;47:697-705.
12.
Yang MD, Wu CC, Chiou SH, Chiu CF, Lin TY, Chiang IP, Chow KC.
Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular
carcinoma. Oncol Rep 2003;10:271-276.
13.
Kawai M, Hosaki S. Clinical usefulness of malate dehydrogenase and its
mitochondrial isoenzyme in comparison with aspartate aminotransferase and its
mitochondrial isoenzyme in sera of patients with liver disease. Clin Biochem
1990;23:327-334.
14.
Hammond KD, Balinsky D. Activities of key gluconeogenic enzymes and
glycogen synthase in rat and human livers, hepatomas, and hepatoma cell cultures.
Cancer Res 1978;38:1317-1322.
15.
Bellisola G, Casaril M, Gabrielli GB, Caraffi M, Corrocher R. Catalase
activity in human hepatocellular carcinoma (HCC). Clin Biochem 1987;20:415-417.
16.
Park KS, Cho SY, Kim H, Paik YK. Proteomic alterations of the variants of
human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma. Int J
Cancer 2002;97:261-265.
17.
Athanassiadou P, Psyhoyiou H, Grapsa D, Gonidi M, Ketikoglou I, Patsouris
E. Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis,
autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. Acta Cytol
2007;51:61-65.
18.
Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS,
Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in
human cancers: a method for identifying cancers sensitive to arginine deprivation.
Cancer 2004;100:826-833.
19.
Kim SZ, Kupke KG, Ierardi-Curto L, Holme E, Greter J, Tanguay RM,
Poudrier J, et al. Hepatocellular carcinoma despite long-term survival in chronic
tyrosinaemia I. J Inherit Metab Dis 2000;23:791-804.
20.
Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano
TJ, et al. Reduced selenium-binding protein 1 expression is associated with poor
outcome in lung adenocarcinomas. J Pathol 2004;202:321-329.
21.
Tan L, Fu XY, Liu SQ, Li HH, Hong Y, Wu MC, Wang HY. Expression of
p28GANK and its correlation with RB in human hepatocellular carcinoma. Liver Int
2005;25:667-676.